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Constitutively Active CaMKKa
Stimulates Skeletal Muscle
Glucose Uptake in Insulin-
Resistant Mice In Vivo
In insulin-sensitive skeletal muscle, the expression
of constitutively active Ca2+/calmodulin-dependent
protein kinase kinase a (caCaMKKa) stimulates
glucose uptake independent of insulin signaling (i.e.,
Akt and Akt-dependent TBC1D1/TBC1D4
phosphorylation). Our objectives were to determine
whether caCaMKKa could stimulate glucose uptake
additively with insulin in insulin-sensitive muscle, in
the basal state in insulin-resistant muscle, and if so,
to determine whether the effects were associated
with altered TBC1D1/TBC1D4 phosphorylation. Mice
were fed a control or high-fat diet (60% kcal) for 12
weeks to induce insulin resistance. Muscles were
transfected with empty vector or caCaMKKa
plasmids using in vivo electroporation. After 2
weeks, caCaMKKa protein was robustly expressed.
In insulin-sensitive muscle, caCaMKKa increased
basal in vivo [3H]-2-deoxyglucose uptake
approximately twofold, insulin increased glucose
uptake approximately twofold, and caCaMKKa plus
insulin increased glucose uptake approximately
fourfold. caCaMKKa did not increase basal TBC1D1
(Ser237, Thr590, Ser660, pan-Thr/Ser) or TBC1D4
(Ser588, Thr642, pan-Thr/Ser) phosphorylation. In
insulin-resistant muscle, caCaMKKa increased
basal glucose uptake approximately twofold, and
attenuated high-fat diet–induced basal TBC1D1
(Thr590, pan-Thr/Ser) and TBC1D4 (Ser588, Thr642,
pan-Thr/Ser) phosphorylation. In cell-free assays,
CaMKKa increased TBC1D1 (Thr590, pan-Thr/Ser)
and TBC1D4 (Ser588, pan-Thr/Ser) phosphorylation.
Collectively, these results demonstrate that
caCaMKKa stimulates glucose uptake additively
with insulin, and in insulin-resistant muscle, and
alters the phosphorylation of TBC1D1/TBC1D4.
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Skeletal muscle is the primary site for insulin-stimulated
glucose disposal in the human body, accounting for
80–90% of all the glucose taken up from the blood (1). In
people with type 2 diabetes, while the ability of insulin to
stimulate muscle glucose uptake is impaired (2), the
ability of non-insulin–dependent stimuli, such as
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exercise/muscle contraction, to increase glucose uptake
remains intact (3). Thus, determination of the intracellular
signaling mechanisms underlying insulin-independent
muscle glucose uptake may identify novel pharmaceutical
targets for the treatment of type 2 diabetes.
Intracellular Ca2+ plays a critical role in numerous
cellular and metabolic processes in muscle, including the
regulation of contractile activity and glucose uptake.
Importantly, studies have shown that stimulation of
isolated rodent muscles with low doses of the
sarcoplasmic reticulum Ca2+ release agents, caffeine or
N-(6-amino-hexyl)-5-chloro-1-napthalenesulfonamide
(W-7), can increase glucose uptake twofold to fourfold,
independent of detectable force development (4–6),
changes in cellular energetics (4), or energetic down-
stream signals (i.e., AMP-activated protein kinase
[AMPK]) (5), demonstrating that Ca2+-dependent
signaling is an independent pathway regulating muscle
glucose uptake.
The signal transduction pathways by which changes in
intracellular Ca2+ levels stimulate muscle glucose uptake
are not well understood, although studies have suggested
a role for the Ca2+-activated, serine/threonine kinase,
Ca2+/calmodulin-dependent protein kinase kinase a
(CaMKKa) in this process. Previous work in rodent
muscle has shown that inhibition of CaMKK signaling
with the chemical CaMKK inhibitor STO-609 signiﬁ-
cantly inhibited contraction-induced glucose uptake,
independent of detriments in force production (7,8). In
addition, the expression of a constitutively active form of
CaMKKa in insulin-sensitive muscle stimulated glucose
uptake by ;2.5-fold and occurred independently of the
phosphorylation of key insulin-signaling proteins (i.e.,
the serine/threonine kinase, Akt [Thr308] and the Rab
GTPase activating proteins TBC1D1/TBC1D4 [phospho-
Akt substrate (PAS)]) (7). Collectively, these studies
suggest a key potential role for CaMKK in the regulation
of insulin-independent muscle glucose uptake. Despite
this evidence, to date, no studies have examined whether
activation of CaMKKa signaling plus insulin stimulation
have additive effects on muscle glucose uptake, or
whether activation of CaMKKa signaling can stimulate
glucose uptake in a model of muscle insulin resistance.
Thus, the objectives of this study were to determine
whether constitutive activation of CaMKKa signaling
could stimulate glucose uptake additively with insulin, or in
insulin-resistant muscle, and if so whether this occurs via
the phosphorylation of Akt, TBC1D1, and/or TBC1D4.
RESEARCH DESIGN AND METHODS
Animals
Experiments were performed in accordance with the East
Carolina University Institutional Animal Care and Use
Committee and the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals. Mice
were housed in cages at 21–22°C with a 12 h light/dark
cycle. Male C57BL/6J mice were fed a chow diet or a 60
kcal% high-fat diet (Research Diets) starting at 6 weeks
of age, and obtained from The Jackson Laboratory (Bar
Harbor, ME) at 16–17 weeks of age. Mice were main-
tained on a chow diet containing 14 kcal% fat (Prolab
RMH 3000; PMI Nutritional International) or the
60 kcal% fat diet for the remainder of the study. Food
and water were available ad libitum.
Assessment of Insulin Resistance
Mice on the diets for 12 weeks were fasted overnight
(;14 h), and blood was taken to assess glucose levels
using a glucometer (LifeScan, Inc.); insulin levels were
determined by ELISA (EMD Millipore). The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated by multiplying fasted blood glucose (in milli-
moles per liter) by fasted blood insulin levels (in milliunits
per liter) and dividing by 22.5. Control and high-fat–diet
mice were randomly divided into three groups to assess ex
vivo muscle glucose uptake, in vivo muscle glucose uptake,
or muscle intracellular signaling proteins. Body weight,
blood glucose, blood insulin, and HOMA-IR levels are
provided for each group separately in Supplementary
Table 1.
Ex Vivo Skeletal Muscle [3H]-2-Deoxyglucose Uptake
Ex vivo muscle glucose uptake was performed using
methods adapted from Witczak et al. (9). Brieﬂy, mice
were fasted overnight, anesthetized with pentobarbital
sodium (100 mg/kg, intraperitoneal), and killed by
cervical dislocation. The extensor digitorum longus
muscles were removed and placed in gassed 37°C Krebs-
Ringer bicarbonate (KRB) solution containing the fol-
lowing (in mmol/L): 117 NaCl, 4.7 KCl, 2.5 CaCl2 $ 2H2O,
1.2 KH2PO4, 1.2 MgSO4 $ 7H2O, and 24.6 NaHCO3
supplemented with 2 pyruvate for 60 min. Muscles were
incubated in KRB plus pyruvate containing 0 or 4,167
pmol/L (600 mU/mL) insulin (Roche Diagnostics) for
20 min, then in KRB buffer containing 1.5 mCi/mL
[3H]-2-deoxyglucose, 1 mmol/L deoxyglucose, 0.45
mCi/mL [14C]-mannitol, and 7 mmol/L mannitol with
or without insulin. Muscles were frozen in liquid N2,
solubilized in 1N NaOH at 80°C and neutralized with
1N HCl. Samples were centrifuged at 11,000g for 1 min.
Aliquots were removed for scintillation counting of the
[3H] and [14C] labels, and [3H]-deoxyglucose uptake
calculated.
Transfection of Mouse Muscle Using In Vivo
Electroporation
Plasmids containing truncated constitutively active
CaMKKa (caCaMKKa) (amino acids 1–434) or empty
vector pCS2+ were donated by Thomas R. Soderling
(Vollum Institute, Oregon Health and Science University,
Portland, OR) (10). Plasmid DNA injections and in vivo
electroporation were performed as previously described
(7,9). For all transfections, plasmid DNA for active
CaMKKa was injected into the tibialis anterior muscle of
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one leg, and empty vector was injected into the contra-
lateral muscle. Muscles were allowed 2 weeks to express
proteins.
In Vivo Skeletal Muscle [3H]-2-Deoxyglucose Uptake
In vivo muscle glucose uptake was assessed using meth-
ods adapted from Witczak and colleagues (7,9). Mice
were fasted overnight and anesthetized with pentobar-
bital sodium. After 30 min, blood was taken from the tail
to assess glucose, insulin, and background radioactivity.
A bolus of [3H]-2-deoxyglucose (0.33 mCi [3H]/g body
weight) dissolved in 0.9% NaCl (4 mL/g body weight) or
20% glucose (1 mg glucose/g body weight) was admin-
istered retro-orbitally, and blood was taken 5, 10, 15, 25,
35, and 45 min later for glucose, [3H]-2-deoxyglucose,
and/or insulin measurements. Mice were killed and
muscles frozen in liquid N2. Muscles were weighed and
homogenized in buffer containing the following (in
mmol/L): 20 Tris-HCl, pH 7.5, 5 EDTA, 10 Na4P2O7, 100
NaF, 2 NaVO4, 0.01 leupeptin, 3 benzamidine, 1
phenylmethylsulfonyl ﬂuoride, and 10 mg/mL aprotinin.
Homogenates were divided for [3H]-2-deoxyglucose
uptake and immunoblot analyses. Accumulation of
muscle radioactivity was assessed using procedures
modiﬁed from Ferré et al. (11), and the rate of glucose
uptake was calculated as previously described (12).
Homogenates not used for uptake measurements were
mixed with 1% Nonidet P-40 and were processed for
immunoblots as described below.
Assessment of Intracellular Signaling by
Immunoprecipitation and Immunoblot Analysis
Intracellular signaling was assessed in muscle expressing
caCaMKKa, as previously described (7). Mice were fasted
overnight and anesthetized with pentobarbital sodium.
After 30 min, blood was taken from the tail to assess
glucose and insulin levels. A bolus of 0.9% NaCl was
administered retro-orbitally, and blood was taken 10 min
later for glucose and insulin measurements. Mice were
killed, and muscles were frozen in liquid N2. Muscles
were homogenized in buffer containing the following (in
mmol/L): 20 Tris-HCl, pH 7.5, 5 EDTA, 10 Na4P2O7, 100
NaF, 2 NaVO4, 1% Nonidet P-40, 0.01 leupeptin, 3
benzamidine, 1 phenylmethylsulfonyl ﬂuoride, and 10
mg/mL aprotinin. Samples were rotated end over end at
4°C for 1 h and centrifuged at 14,000g for 30 min.
Protein concentrations were determined via the Bradford
method.
Immunoprecipitation was performed using standard
methods (7). Brieﬂy, muscle lysates (400 mg for TBC1D1;
800 mg for TBC1D4) were incubated with TBC1D1 or
TBC1D4 antibodies and protein G beads in buffer
containing the following (in mmol/L): 20 Tris-HCl, pH 7.6,
200 NaCl, 5 EDTA, 1% Triton X-100, 10 mg/mL aprotinin,
0.01 leupeptin, 3 benzamidine, 1 phenylmethylsulfonyl
ﬂuoride, 100 NaF, and 2 NaVO4 at 4°C. The supernatant
was removed, and beads were washed four times. Laemmli
buffer was added, and samples were heated at 95°C for 5
min.
Immunoblots were performed using standard meth-
ods (13). Brieﬂy, muscle lysates (20–60 mg) or
immunoprecipitates were subjected to SDS-PAGE, and
proteins were transferred onto nitrocellulose membranes
and then incubated with one of the following primary
antibodies: phospho-Akt (Thr308), phospho-Akt
(Ser473), pan-Akt, phospho-AMPK (Thr172), AMPKa,
phospho-TBC1D1 (Thr590), phospho-TBC1D1 (Ser660),
TBC1D1, phospho-TBC1D4 (Ser588), phospho-TBC1D4
(Thr642), phospho-pan-Thr (Thr/Ser) from Cell
Signaling Technology; GLUT1, GLUT4, phospho-TBC1D1
(Ser237), TBC1D4 from Millipore; and CaMKKa (F-2),
Hexokinase II from Santa Cruz Biotechnology. Horse-
radish peroxide–conjugated secondary antibodies were
incubated with the membrane and detected using
chemiluminescence reagents (PerkinElmer).
Densitometric analysis was performed using Image Lab
software (Bio-Rad).
Cell-Free Phosphorylation Assays
Myc-tagged human TBC1D1 or TBC1D4 (OriGene
Technologies) proteins (0.3 mg) were incubated in buffer
containing the following (in mmol/L): 50 HEPES, pH 7.4,
1 EGTA, pH 8.0, 1 dithiothreitol, 10 Mg-acetate $ 4H2O,
and 0.1 ATP, with or without 7 mmol/L calmodulin and 4
mmol/L CaCl2, with or without 0.1 mg human CaMKKa
isoform a (SignalChem) at 37°C for 30 min. Reactions
were terminated by the addition of Laemmli buffer and
heated at 95°C for 5 min. Reaction mixtures were
subjected to immunoblot analysis as described above.
Statistical Analysis
Data are presented as the mean 6 SEM. Statistical
signiﬁcance was deﬁned as P , 0.05 and was determined
by Student t tests or two-way ANOVA and Student-
Newman-Keuls post hoc analysis. The number of mice or
muscles used to determine signiﬁcance is indicated in the
text or ﬁgure legends.
RESULTS
caCaMKKa Plus Insulin Has Additive Effects on
Muscle Glucose Uptake
Previous work has shown that the expression of
caCaMKKa in insulin-sensitive muscle increased glucose
uptake ;2.5-fold independent of insulin signaling (7),
suggesting that CaMKKa may play a critical role in the
regulation of insulin-independent muscle glucose uptake.
However, to date, no studies have examined whether
expression of caCaMKKa and insulin have additive effects
on muscle glucose uptake. To address this goal, muscles
from insulin-sensitive mice were transfected with
plasmids containing empty vector or caCaMKKa using in
vivo electroporation. Two weeks later, in vivo muscle glu-
cose uptake was assessed in the basal state or in response
to a physiological insulin response (i.e., intravenous glucose
injection). As shown in Fig. 1A and B, intravenous glucose
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signiﬁcantly increased blood glucose and insulin levels,
demonstrating that these procedures elicit insulin
secretion from the pancreas. caCaMKKa increased basal
glucose uptake approximately twofold (Fig. 1C), while
insulin-stimulated glucose uptake increased approximately
twofold (Fig. 1C), consistent with previous ﬁndings in
insulin-sensitive muscle (7,9). The combination of
caCaMKKa plus insulin increased glucose uptake approxi-
mately fourfold (Fig. 1C), demonstrating that activation of
CaMKKa signaling plus insulin can additively increase
glucose uptake into muscle. To assess whether CaMKKa
expression was the same in both treatment groups,
immunoblots were performed. Importantly, in the same
muscles used to assess glucose uptake, there was no sig-
niﬁcant difference in caCaMKKa expression (Fig. 1D). The
ratio of caCaMKKa to endogenous CaMKKa was assessed
in immunoblots at the exact same exposure time, and was
calculated to be 55.26 7.3 and 69.86 10.6 in the muscles
from the saline-injected and glucose-injected mice, re-
spectively. It was not statistically different (P = 0.276)
between the treatment groups.
High-Fat Diet–Induced Skeletal Muscle Insulin
Resistance
Since caCaMKKa plus insulin had additive effects on
muscle glucose uptake, next it was important to
determine whether caCaMKKa could stimulate glucose
uptake in insulin-resistant muscle. To generate a model
of muscle insulin resistance, male C57BL/6J mice were
fed a high-fat diet for 12 weeks. As shown in Table 1,
mice receiving a high-fat diet exhibited signiﬁcant
Figure 1—Expression of caCaMKKa and insulin stimulation additively increase glucose uptake in mouse skeletal muscle in vivo. Blood
glucose (A) and serum insulin (B) levels were assessed for 45 min following a retro-orbital injection of [3H]-2-deoxyglucose dissolved in
saline (intravenous saline) or a 20% glucose solution (intravenous glucose) to elicit insulin release from the pancreas. C: Muscle glucose
uptake was assessed in tibialis anterior muscles transfected with empty vector or caCaMKKa for 2 weeks. D: Representative immunoblots
and quantiﬁcation to assess caCaMKKa and endogenous CaMKKa expression. Statistical signiﬁcance was deﬁned as P < 0.05: *vs.
intravenous saline (basal); $vs. 0 min; #vs. empty vector; ^main treatment effect vs. empty vector. n = 12–13 mice or muscles per
treatment group. IB, immunoblot.
Table 1—12-Week high-fat diet induces insulin resistance in
male C57BL/6J mice
Characteristics
Treatment group
Control diet
(N = 37)
High-fat diet
(N =38)
Age (weeks) 18 6 0 18 6 0
Body weight (g) 26.2 6 0.3 34.8 6 0.7*
Fasted blood glucose
(mmol/L) 6.7 6 0.3 9.6 6 0.4*
Fasted serum insulin (pmol/L) 53.8 6 3.3 121.9 6 15.2*
HOMA-IR (mmol/L 3 mU/L) 2.2 6 0.1 7.3 6 1.0*
Mice were fed either a low-fat (control) or a high-fat (60 kcal%)
diet for 12 weeks starting at 6 weeks of age. After an overnight
fast, mice were weighed and blood samples were taken to
assess glucose and insulin levels, and to calculate HOMA-IR.
*Statistical signiﬁcance was deﬁned as P , 0.05 vs. control
diet.
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increases in blood glucose and insulin levels, and
HOMA-IR, demonstrating that the high-fat diet–induced
systemic insulin resistance. To examine muscle insulin
resistance, insulin-stimulated ex vivo muscle glucose
uptake was measured in a subset of mice. As shown in
Fig. 2, muscles from the high-fat–fed mice exhibited
signiﬁcantly impaired insulin-stimulated glucose uptake
conﬁrming muscle insulin resistance in these animals.
caCaMKKa Stimulates Glucose Uptake in Insulin-
Resistant Muscle
To determine whether activation of CaMKKa signaling
could stimulate glucose uptake in insulin-resistant mus-
cle, muscles from control and high-fat diet–fed mice were
transfected with empty vector or caCaMKKa. Two weeks
later, mice were injected with [3H]-2-deoxyglucose to
assess muscle glucose uptake. As shown in Fig. 3A and B,
the intravenous saline injection did not elicit a signiﬁcant
change in blood glucose or insulin levels in either the
control or high-fat diet–fed mice. In both the control and
high-fat–fed mice, caCaMKKa increased muscle glucose
uptake by approximately twofold (Fig. 3C), demonstrat-
ing that the activation of CaMKKa signaling can increase
glucose uptake in both insulin-sensitive and insulin-
resistant muscle. Immunoblots were performed to assess
CaMKKa protein levels, and there was no signiﬁcant
difference in caCaMKKa expression (Fig. 3D). The mean
ratios of caCaMKKa to endogenous CaMKKa were
43.0 6 14.2 and 74.7 6 18.5 in the muscles from the
control and high-fat diet–fed mice, respectively, and were
not statistically different (P = 0.207).
Figure 2—A 12-week high-fat diet induces skeletal muscle insulin
resistance in male C57BL/6J mice. In mice fed either a control diet
or a high-fat diet for 12 weeks, muscle glucose uptake was
assessed in isolated extensor digitorum longus muscles in re-
sponse to insulin (4,167 pmol/L = 600 mU/mL). Statistical signiﬁ-
cance was deﬁned as P < 0.05: *vs. basal; #vs. control diet.
n = 6–8 muscles per treatment group.
Figure 3—Expression of caCaMKKa stimulates glucose uptake in the skeletal muscle of insulin-resistant mice in vivo. Blood glucose
(A) and serum insulin (B) levels were assessed for 45 min after a retro-orbital injection of [3H]-2-deoxyglucose dissolved in saline.
C: Muscle glucose uptake was assessed in tibialis anterior muscles transfected with empty vector or caCaMKKa for 2 weeks. D: Rep-
resentative immunoblots and quantiﬁcation to assess caCaMKKa and endogenous CaMKKa expression. Statistical signiﬁcance was
deﬁned as P < 0.05: *vs. control diet; #vs. empty vector. n = 7–8 mice or muscles per treatment group. IB, immunoblot.
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caCaMKKa Does Not Stimulate TBC1D1/TBC1D4
Phosphorylation on Akt- or AMPK-Dependent Sites in
Muscle
Insulin stimulates muscle glucose uptake via a relatively
well-characterized signaling cascade, involving the
phosphorylation of Akt, TBC1D1, and TBC1D4 (reviewed
in Sakamoto and Holman [14]). Previous work in insulin-
sensitive muscle showed that caCaMKKa stimulated
glucose uptake independent of an increase in Akt
(Thr308) and TBC1D1/TBC1D4 (PAS) phosphorylation
(7), suggesting that CaMKKa stimulates glucose uptake
independent of insulin signaling. However, since the
publication of that manuscript a large number of phos-
phorylation sites have been identiﬁed on TBC1D1 and
TBC1D4 that have been implicated in the regulation of
muscle glucose uptake, and speciﬁc antibodies made
against some of them. Thus, it was next important to
determine whether caCaMKKa increased glucose uptake
in insulin-resistant muscle via phosphorylation of Akt,
TBC1D1, or TBC1D4.
As shown in Fig. 4, in the muscles used for intracellular
signaling, the ratio of active to endogenous CaMKKa was
32.7 6 3.8 (control diet) and 29.5 6 2.6 (high-fat diet),
and was not statistically different (P = 0.496). In both the
control and insulin-resistant muscles, caCaMKKa did not
increase the basal phosphorylation of Akt (Thr308) or
(Ser473), pan-Akt expression, or the ratio of phosphory-
lated to total pan-Akt (Fig. 4). Thus, phosphorylation of
Akt is not the mechanism for CaMKKa-induced glucose
uptake. To examine whether CaMKKa could be
stimulating glucose uptake via TBC1D1 or TBC1D4
phosphorylation on known Akt sites, immunoblots were
performed to assess TBC1D1 (Thr590), TBC1D4 (Ser588),
and TBC1D4 (Thr642) phosphorylation, as well as TBC1D1
and TBC1D4 protein levels. In both the control and
insulin-resistant muscles, caCaMKKa did not increase
TBC1D1 or TBC1D4 protein expression or basal phos-
phorylation on any of these sites (Fig. 4). In the insulin-
resistant muscles, there was a signiﬁcant increase in the
basal phosphorylation of TBC1D1 (Thr590) and TBC1D4
(Ser588) that was attenuated by caCaMKKa (Fig. 4), sug-
gesting that CaMKKa-mediated signaling could be
inducing TBC1D1/TBC1D4 phosphorylation on sites that
compete with other phosphorylation sites.
AMPK is a known substrate of CaMKKa, and previous
work has shown that caCaMKKa expression stimulated
an approximately twofold increase in AMPK (Thr172)
phosphorylation and activity in insulin-sensitive muscle
(7). Since AMPK can phosphorylate TBC1D1 (Ser237,
Ser660) and TBC1D4 (Ser711), we next examined whether
active CaMKKa could be inducing TBC1D1/TBC1D4
phosphorylation on AMPK-dependent sites. Since there
are currently no commercially available antibodies for
phosphorylated TBC1D4 (Ser711), only phosphorylated
TBC1D1 (Ser237, Ser660) was examined. In control
muscles under basal conditions (i.e., without glucose
stimulation), despite an approximately twofold increase
in AMPK (Thr172) phosphorylation, caCaMKKa did not
increase TBC1D1 (Ser237) or (Ser660) phosphorylation
(Fig. 4). In the insulin-resistant muscles under basal
conditions, there was a signiﬁcant increase in the basal
phosphorylation of TBC1D1 (Ser237) and TBC1D1
(Ser660), and this increase was not affected by caCaMKKa
(Fig. 4). Thus, caCaMKKa is not stimulating TBC1D1/
TBC1D4 phosphorylation on AMPK-dependent sites.
To assess whether caCaMKKa could be altering
TBC1D1/TBC1D4 phosphorylation on Thr/Ser residues
not examined with the site-speciﬁc phospho-antibodies,
TBC1D1 or TBC1D4 was immunoprecipitated from
muscle lysates and global Thr/Ser phosphorylation was
assessed. As shown in Fig. 4, in control muscles
caCaMKKa did not alter TBC1D1 or TBC1D4 (pan-Thr/
Ser) phosphorylation. In the insulin-resistant muscles,
pan-Thr/Ser phosphorylation was signiﬁcantly increased
on TBC1D1, and there was a tendency for it to be
increased on TBC1D4 (P = 0.08); caCaMKKa attenuated
those increases. These results are consistent with those
obtained using the site-speciﬁc phospho-antibodies for
Akt-dependent sites, but not AMPK-dependent sites.
In a Cell-Free Assay, CaMKKa Can Phosphorylate
TBC1D1 and TBC1D4
In insulin-resistant muscle, caCaMKKa alters the phos-
phorylation status of TBC1D1 and TBC1D4. To test
whether this could be occurring via direct phosphorylation
of TBC1D1/TBC1D4 by CaMKKa, cell-free phosphoryla-
tion assays were performed. As shown in Fig. 5A, in the
presence of CaMKKa and Ca2+/calmodulin there was
a signiﬁcant increase in TBC1D1 and TBC1D4 (pan-Thr/
Ser) phosphorylation, demonstrating that CaMKKa can
function as an upstream kinase for TBC1D1 and TBC1D4.
To examine whether this increase in pan-Thr/Ser phos-
phorylation could be occurring via phosphorylation of
Akt- or AMPK-dependent sites, the experiments were
repeated using the TBC1D1/TBC1D4 site-speciﬁc
phospho-antibodies. As shown in Fig. 5B and C, in the cell-
free assay CaMKKa stimulated phosphorylation of
TBC1D1 (Thr590) and TBC1D4 (Ser588), but not TBC1D1
(Ser237), TBC1D1 (Ser660), or TBC1D4 (Thr642), demon-
strating that CaMKKa can phosphorylate TBC1D1 and
TBC1D4 on some Akt- but not AMPK-speciﬁc sites.
caCaMKKa Does Not Increase GLUT1, GLUT4, or
Hexokinase II Protein Levels
To evaluate the possibility that in insulin-resistant
muscles caCaMKKa stimulates glucose uptake by
increasing the expression of proteins involved in the
transport or phosphorylation of glucose, immunoblot
analyses were performed to examine GLUT1, GLUT4, and
hexokinase II. Expression of caCaMKKa did not signiﬁ-
cantly alter GLUT1, GLUT4, or hexokinase II protein levels
(Fig. 5), demonstrating that increases in the expression of
these proteins does not account for the ability of CaMKKa
to regulate glucose uptake.
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Figure 4—Active CaMKKa does not stimulate muscle glucose uptake via stimulation of Akt, Akt-dependent, or AMPK-dependent
phosphorylation on TBC1D1 or TBC1D4. Tibialis anterior muscles from mice fed either a control diet or a high-fat diet for 12 weeks were
transfected with DNA vectors containing empty vector or caCaMKKa. After 2 weeks, muscles were excised and processed for immu-
noprecipitation and/or immunoblot analyses. Representative immunoblots and quantiﬁcation for the phosphorylation or expression of
CaMKKa, AMPK, Akt, TBC1D1, and TBC1D4. Statistical signiﬁcance was deﬁned as P < 0.05: *vs. control diet; #vs. empty vector;
^denotes a main treatment vs. control diet. n = 7–10 muscles per treatment group. IB, immunoblot; IP, immunoprecipitation.
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DISCUSSION
The data presented in this study are the ﬁrst to demon-
strate that the expression of caCaMKKa in mouse muscle
can increase glucose uptake in a manner additive with
insulin in insulin-sensitive muscles, and in the basal state
in insulin-resistant muscles. In addition, although
caCaMKKa expression does not increase TBC1D1 or
TBC1D4 phosphorylation on Akt- or AMPK-dependent
sites in muscle, in cell-free assays CaMKKa can function
as a TBC1D1/TBC1D4 kinase, raising the possibility that
CaMKKa-mediated TBC1D1/TBC1D4 phosphorylation
on unique sites could be part of the mechanism
underlying CaMKKa-induced muscle glucose uptake.
In this study, a high level of caCaMKKa protein
expression was achieved relative to endogenous protein
levels (Figs. 1D, 3D, and 4, and Supplementary Fig. 1).
The physiological relevance of this high expression is
difﬁcult to assess because a truncated form of CaMKKa
that would not normally be found in a mammalian cell
was used. However, a study by McGee et al. (15) dem-
onstrated that in mouse plantaris muscle 1 week of hy-
pertrophic growth increased endogenous CaMKKa
protein levels by approximately fourfold and CaMKKb
protein levels by ;50-fold. Thus, there is precedent for
mouse muscle to experience a large increase in CaMKK
protein content in response to a physiological stimulus.
To assess the relationship of active CaMKKa protein
levels and muscle glucose uptake, we performed a linear
regression analysis. Importantly, we did not observe
a signiﬁcant correlation between the amount of
caCaMKKa and the increase in glucose uptake (Supple-
mentary Fig. 1). Thus, active CaMKKa protein expression
across a wide range (;15- to 200-fold) does not affect
the ability of the muscle to transport glucose.
Male C57BL/6J mice fed a 60 kcal% fat diet for 12
weeks exhibited signiﬁcantly elevated fasted blood glu-
cose and insulin levels, as well as reduced insulin-
stimulated muscle glucose uptake (Fig. 2, Table 1, and
Supplementary Table 1), consistent with numerous
studies reporting hyperglycemia (16–19), hyper-
insulinemia (16–19), and muscle insulin resistance
(18,19) in C57BL/6 mice fed a high-fat diet. Importantly,
although muscle insulin resistance and the ability of
caCaMKKa to stimulate glucose uptake were not
assessed in muscles from the same high-fat diet–fed
mice, none of the mouse phenotypic characteristics were
signiﬁcantly different between the subsets (Supplemen-
tary Table 1). Thus, the level of muscle insulin resistance
observed in one high-fat diet subset should be compa-
rable to the other. Unfortunately, since the in vivo glu-
cose uptake experiments require the systemic injection of
[3H]-2-deoxyglucose, we could not assess insulin-induced
muscle glucose uptake in the same mice.
Insulin resistance was assessed in extensor digitorum
longus muscles (Fig. 2), whereas the ability of caCaMKKa
to stimulate glucose uptake was assessed in tibialis an-
terior muscles (Fig. 3). Unfortunately, the relatively large
size (;45 mg) and irregular shape of the tibialis anterior
prohibits its use in ex vivo studies because of limited
oxygen diffusion to the interior ﬁbers. The extensor
digitorum longus is a relatively small (;10 mg), cylin-
drically shaped muscle and shares a similar ﬁber-type
composition to the tibialis anterior (;88% vs. 93% type
Figure 5—CaMKKa phosphorylates TBC1D1 and TBC1D4 in
a cell-free assay. Recombinant, full-length, Myc-tagged TBC1D1
and TBC1D4 proteins (0.3 mg) were incubated in the presence or
absence of ;3 mmol/L free Ca2+ plus 7 mmol/L calmodulin
(Ca2+/CaM) and/or recombinant GST-tagged CaMKKa isoform
a (0.1 mg). A: TBC1D1 and TBC1D4 phosphorylation using a pan-
phospho-Thr/Ser antibody. B: TBC1D1 phosphorylation on
Ser237, Thr590, and Ser660. C: TBC1D4 phosphorylation on
Ser588 and Thr642. Representative immunoblots and membrane
stains for total protein from three independent experiments. IB,
immunoblot.
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IIB plus type IIDB ﬁbers, respectively) (20). Thus, insulin
resistance observed in the extensor digitorum longus
should be comparable to that in the tibialis anterior.
Despite an approximately twofold increase in glucose
uptake in muscles expressing caCaMKKa, we did not
observe a signiﬁcant lowering of blood glucose or insulin
levels in the insulin-resistant mice (Supplementary Table
2). This result was not unexpected because a single
tibialis anterior muscle (;60 mg) accounts for only
;0.3% of the total body mass of a 20-week-old, chow-
fed, male C57BL/6J mouse (average body weight in this
study ;26 g).
caCaMKKa increased glucose uptake to the same
extent in both insulin-sensitive and insulin-resistant
muscle (Fig. 3), suggesting that CaMKKa signaling
stimulates glucose uptake via an insulin-independent
signaling pathway. Our results are consistent with data
obtained in isolated mouse muscles, which demon-
strated that inhibition of CaMKK with the chemical
inhibitor STO-609 signiﬁcantly inhibited caffeine-
induced (6) and contraction-induced glucose uptake
(7,8), but not insulin-induced glucose uptake (7).
In both insulin-sensitive and insulin-resistant
muscles, caCaMKKa did not increase Akt phosphorylation
or protein levels (Fig. 4). These results were consistent
with previous work that demonstrated no change in Akt
(Thr308) phosphorylation or Akt1/2 protein levels in
response to active CaMKKa expression (7). Thus,
insulin resistance had no effect on the ability/inability
of CaMKKa to phosphorylate Akt. These results were
not consistent with previous cell-free or cell culture
studies that showed that CaMKKa can phosphorylate
Akt (Thr308) (21). The reason behind the lack of
CaMKKa-Akt signaling in muscle is not known,
although it could be due to tissue-speciﬁc differences in
CaMKKa function, subcellular localization, and/or lack
of necessary cofactors.
Previous work has shown that insulin stimulates
phosphorylation of TBC1D1 on Thr253 and Thr590
(22,23); and of TBC1D4 on Ser318, Ser588, Thr642, Ser711,
and Ser751 (24,25). Whereas phospho-antibodies for
TBC1D1 (Thr253), TBC1D4 (Ser711), and TBC1D4 (Ser751)
are currently unavailable, we were able to examine
TBC1D1 (Thr590), TBC1D4 (Ser588), and (Thr642) phos-
phorylation. In insulin-sensitive and insulin-resistant
muscle, caCaMKKa did not increase TBC1D1 (Thr590),
TBC1D4 (Ser588), or (Thr642) phosphorylation (Fig. 4),
consistent with data showing that activation of
CaMKKa signaling regulates glucose uptake via an
insulin/Akt-independent pathway. Intriguingly, in
insulin-resistant muscle, caCaMKKa signiﬁcantly de-
creased TBC1D1 (Thr590) and attenuated TBC1D4
(Ser588) phosphorylation (Fig. 4), raising the possibility
that active CaMKKa inhibits this phosphorylation by
stimulating phosphorylation on another residue.
Consistent with this hypothesis, in cell-free assays
CaMKKa can phosphorylate TBC1D1 and TBC1D4 on
Thr/Ser residues (Fig. 5). This result was initially
surprising since previous cell-free studies had demon-
strated that CaMKKb is not able to phosphorylate
TBC1D1/TBC1D4 (PAS) (26). However, there are several
possible explanations for the difference in these ﬁndings
including different CaMKK isoforms (CaMKKa vs.
CaMKKb), assay conditions (calmodulin vs. no calmodu-
lin), as well as the primary antibody (pan-Thr/Ser vs. PAS
antibody). Importantly, the results from our cell-free
assays are not evidence that CaMKKa phosphorylates
TBC1D1/TBC1D4 in muscle, and additional studies are
still needed to determine the potential signiﬁcance of this
interaction for muscle glucose uptake.
In control and insulin-resistant muscle, caCaMKKa
increased glucose uptake independent of changes in
GLUT1, GLUT4, or hexokinase II protein expression
(Fig. 6). Importantly, these data do not account for
possible relocalization of glucose transporters to the
membrane, as this could also lead to increases in glucose
uptake. Determination of the GLUTs that are mediating
CaMKKa-induced glucose uptake is a topic of future
investigation.
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